A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis

Inclusion Criteria:

- Subjects must have a time since diagnosis of adult-onset Rheumatoid Arthritis (RA)
less than 1 year as defined by the 2010 ACR/EULAR classification criteria from
Screening Visit

- Positive Rheumatoid Factor (RF) and/or positive anticyclic Citrullinated Peptide
Antibody (anti-CCP)

- Active RA disease

- DMARD-naïve

- Subject is naïve to RA related biologics

Exclusion Criteria:

- A diagnosis of any other inflammatory Arthritis

- History of infected joint prosthesis, or other significant infection and other serious
medical condition

- Known Tuberculosis (TB) disease or high risk of acquiring TB infection